Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.6K
Pneumonia IV: Management01:28

Pneumonia IV: Management

403
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
403
Pneumothorax-II01:27

Pneumothorax-II

224
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
224
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

15
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
15
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

256
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
256
Radiological Investigation II: MRI and Ventilation Perfusion Scan01:30

Radiological Investigation II: MRI and Ventilation Perfusion Scan

160
Description
Magnetic Resonance Imaging (MRI) and Ventilation Perfusion Scans are two radiological investigations that offer detailed diagnostic images of the body, particularly lung structures.
MRI
MRI uses magnetic fields and radiofrequency signals to distinguish between normal and abnormal tissues. This technology provides a more detailed diagnostic image than CT scans, enabling it to characterize pulmonary nodules, stage bronchogenic carcinoma, and evaluate inflammatory activity in...
160

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of a diagnostic bronchoscopy in hypersensitivity pneumonitis.

PloS one·2023
Same author

Post-infection pulmonary sequelae after COVID-19 among patients with lung transplantation.

Transplant infectious disease : an official journal of the Transplantation Society·2021
Same author

Defining natural history: assessment of the ability of college students to aid in characterizing clinical progression of Niemann-Pick disease, type C.

PloS one·2011
See all related articles

Related Experiment Video

Updated: Jul 29, 2025

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.2K

Post COVID Interstitial Lung Abnormalities-Incidence and Management.

Mark Robertshaw1, Corey D Kershaw1

  • 1Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, 5939 Harry Hines Blvd, 75390-8558 Dallas, TX USA.

Current Pulmonology Reports
|May 19, 2023
PubMed
Summary

Up to 30% of patients hospitalized with COVID-19 develop persistent interstitial lung abnormalities (ILAs). While most ILAs improve, about one-third may show irreversible fibrosis, requiring ongoing pulmonary management.

Keywords:
COVID-19Interstitial lung abnormalityInterstitial lung diseasePost-COVIDPost-COVID fibrosis

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K
Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation
07:28

Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation

Published on: October 11, 2024

392

Related Experiment Videos

Last Updated: Jul 29, 2025

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.2K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K
Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation
07:28

Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation

Published on: October 11, 2024

392

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Radiology

Background:

  • COVID-19 hospitalizations have led to a growing number of patients with persistent lung issues.
  • Interstitial lung abnormalities (ILAs) are a common sequela observed post-COVID-19 hospitalization.

Purpose of the Study:

  • To review the current literature on the incidence and risk factors of persistent ILAs after COVID-19 hospitalization.
  • To summarize available and emerging treatment options for post-COVID-19 ILAs.

Main Methods:

  • Literature review of studies reporting on lung abnormalities following COVID-19 hospitalization.
  • Analysis of incidence rates and identified risk factors for persistent ILAs.
  • Evaluation of current and prospective therapeutic strategies.

Main Results:

  • Evidence suggests up to 30% of hospitalized COVID-19 patients develop ILAs.
  • A majority of these ILAs show improvement or resolution over time.
  • Statistical modeling indicates approximately 11.7% of patients may have irreversible fibrotic changes on long-term follow-up.

Conclusions:

  • Persistent ILAs are a significant concern for patients post-COVID-19 hospitalization.
  • While many ILAs resolve, a substantial subset may develop irreversible fibrosis.
  • Pulmonary practitioners will increasingly encounter and manage this patient population, with anti-fibrotic trials underway.